+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05857332

Phase 1 Study of SG1906 for Patients With CLDN18.2-Positive Advanced or Metastatic Solid Tumors

Led by Hangzhou Sumgen Biotech Co., Ltd. · Updated on 2026-08-11

60

Participants Needed

9

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety, tolerability, pharmacokinetics, and early effectiveness of SG1906 in patients with CLDN18.2-positive locally advanced unresectable or metastatic solid tumors. It is a Phase IaIb clinical trial focusing on patients who have relapsed after, failed, or are intolerant to standard therapies. The trial includes patients with specific types of solid tumors, including gastricgastroesophageal junction adenocarcinoma and pancreatic cancer. Patients will receive SG1906 through intravenous infusion every two weeks. Phase Ia involves dose escalation using seven dose levels from 0.1 mgkg to 12 mgkg to find the recommended dose. Phase Ib expands treatment to more patients with confirmed CLDN18.2-positive tumors. Treatment continues until disease progression, intolerable side effects, new anticancer therapy, consent withdrawal, loss to follow-up, death, or study end. Participants will be closely monitored with tumor tissue testing for CLDN18.2, evaluations of organ function, and assessments of adverse events and drug levels. Researchers will measure safety outcomes such as treatment-related adverse events and maximum tolerated dose, as well as pharmacokinetics and immunogenicity over about one year. The study will also evaluate preliminary efficacy and receptor occupancy throughout the study duration.

CONDITIONS

Brief Title

SG1906 for CLDN18.2-Positive Solid Tumors

Research Team

P

Pengyu Shi

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here